X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7556) 7556
Newsletter (45) 45
Magazine Article (33) 33
Newspaper Article (8) 8
Book Chapter (7) 7
Book / eBook (5) 5
Dissertation (4) 4
Book Review (1) 1
Conference Proceeding (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5526) 5526
quinolines - therapeutic use (4482) 4482
male (3015) 3015
female (2692) 2692
animals (2567) 2567
quinolines - pharmacology (2194) 2194
adult (1610) 1610
pharmacology & pharmacy (1538) 1538
middle aged (1495) 1495
quinolines - administration & dosage (1183) 1183
mice (1088) 1088
aged (956) 956
treatment outcome (955) 955
acetates - therapeutic use (953) 953
quinolines - adverse effects (918) 918
fluoroquinolones (866) 866
adolescent (840) 840
oncology (687) 687
asthma - drug therapy (654) 654
rats (640) 640
drug therapy, combination (627) 627
quinoline (618) 618
child (613) 613
montelukast (588) 588
analysis (576) 576
leukotriene antagonists - therapeutic use (569) 569
dose-response relationship, drug (568) 568
aza compounds - therapeutic use (566) 566
double-blind method (548) 548
quinolines - chemistry (518) 518
research (518) 518
cancer (511) 511
asthma (496) 496
moxifloxacin (495) 495
drug therapy (492) 492
quinolines - pharmacokinetics (489) 489
cell line, tumor (479) 479
antimalarials - therapeutic use (475) 475
chemistry, medicinal (463) 463
anti-asthmatic agents - therapeutic use (459) 459
immunology (421) 421
anti-bacterial agents - therapeutic use (415) 415
antineoplastic agents - therapeutic use (415) 415
infectious diseases (412) 412
quinolines (411) 411
microbiology (401) 401
health aspects (400) 400
care and treatment (391) 391
time factors (387) 387
disease models, animal (375) 375
young adult (363) 363
in-vitro (362) 362
expression (359) 359
child, preschool (352) 352
malaria (348) 348
administration, oral (344) 344
clinical trials as topic (344) 344
therapy (344) 344
pharmacokinetics (341) 341
biochemistry & molecular biology (338) 338
drug resistance (337) 337
antineoplastic agents - pharmacology (336) 336
anti-infective agents - therapeutic use (319) 319
malaria - drug therapy (319) 319
efficacy (316) 316
research article (314) 314
apoptosis (310) 310
microbial sensitivity tests (308) 308
inflammation (306) 306
respiratory system (303) 303
children (295) 295
acetates - administration & dosage (287) 287
medicine & public health (287) 287
clinical trials (286) 286
structure-activity relationship (286) 286
allergy (284) 284
pharmacology/toxicology (283) 283
medicine, general & internal (277) 277
drugs (274) 274
aged, 80 and over (271) 271
safety (271) 271
pharmacology (270) 270
prospective studies (269) 269
proteins (268) 268
resistance (266) 266
cell biology (254) 254
abridged index medicus (252) 252
cell proliferation - drug effects (252) 252
inhibition (252) 252
double-blind (249) 249
plasmodium falciparum - drug effects (249) 249
protein kinase inhibitors - therapeutic use (248) 248
medicine (245) 245
quinolines - chemical synthesis (245) 245
cardiac & cardiovascular systems (231) 231
rats, sprague-dawley (231) 231
drug combinations (230) 230
studies (229) 229
apoptosis - drug effects (228) 228
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (228) 228
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6962) 6962
German (197) 197
French (140) 140
Russian (109) 109
Japanese (105) 105
Chinese (62) 62
Spanish (55) 55
Italian (38) 38
Portuguese (21) 21
Polish (20) 20
Czech (12) 12
Dutch (10) 10
Romanian (10) 10
Hungarian (9) 9
Turkish (8) 8
Swedish (6) 6
Bulgarian (3) 3
Croatian (3) 3
Ukrainian (3) 3
Norwegian (2) 2
Hebrew (1) 1
Korean (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | UROLOGY & NEPHROLOGY | PHASE-II | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Head & Neck, ISSN 1043-3074, 05/2012, Volume 34, Issue 5, pp. 736 - 745
The incidence of thyroid cancer continues to increase and this neoplasia remains the most common endocrine malignancy. No effective systemic treatment... 
epidermal growth factor (EGF) | RET | immunomodulator | vascular disrupting agent | multi‐kinase inhibitor | vascular endothelial growth factor (VEGF) | thyroid cancer | histone acetylation | B‐Raf | heat shock protein (HSP) | multi-kinase inhibitor | B-Raf | SURGERY | HISTONE DEACETYLASE INHIBITOR | SUBEROYLANILIDE HYDROXAMIC ACID | ABL TYROSINE KINASE | PROTEASOME INHIBITION | CELL-CYCLE ARREST | VALPROIC ACID | DEPSIPEPTIDE FR901228 | PHASE-II TRIAL | OTORHINOLARYNGOLOGY | IMATINIB MESYLATE | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bibenzyls - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Proto-Oncogene Proteins c-kit - antagonists & inhibitors | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Valproic Acid - therapeutic use | Depsipeptides - therapeutic use | Imidazoles - therapeutic use | Lactams, Macrocyclic - therapeutic use | Pyrroles - therapeutic use | Pyridines - therapeutic use | Bortezomib | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Piperazines - therapeutic use | Imatinib Mesylate | Sulfonamides - therapeutic use | Thyroid Neoplasms - drug therapy | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Quinolines - therapeutic use | Benzamides | Thalidomide - therapeutic use | Benzoquinones - therapeutic use | Indazoles - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD009764
Background There has been renewal of interest in the use of prophylactic antibiotics to reduce the frequency of exacerbations and improve quality of life in chronic obstructive pulmonary disease (COPD... 
Fluoroquinolones | Quinolines | Clarithromycin | Lungs & airways | Drug Administration Schedule | Pulmonary Disease, Chronic Obstructive | Azithromycin | Antibiotic Prophylaxis | Roxithromycin | Erythromycin | Moxifloxacin | Disease Progression | Randomized Controlled Trials as Topic | Trimethoprim, Sulfamethoxazole Drug Combination | Chronic obstructive pulmonary disease (stable) | Amoxicillin | Anti‐Bacterial Agents | Aza Compounds | Clavulanic Acid | Quality of Life | Chronic obstructive pulmonary disease, stable ‐ pharmacotherapy | Medicine General & Introductory Medical Sciences | Other medications | Azithromycin [therapeutic use] | STABLE COPD | Humans | AIRWAY INFLAMMATION | Quinolines [therapeutic use] | Anti-Bacterial Agents [therapeutic use] | MEDICINE, GENERAL & INTERNAL | DAILY PENICILLIN | Aza Compounds [therapeutic use] | TETRACYCLINE | Erythromycin [therapeutic use] | CHRONIC-BRONCHITIS | LONG-TERM AZITHROMYCIN | Antibiotic Prophylaxis [methods] | Pulmonary Disease, Chronic Obstructive [drug therapy] | ACUTE EXACERBATIONS | INDUCED SPUTUM | Clarithromycin [therapeutic use] | DOUBLE-BLIND | Aged | HEALTH-STATUS | Aza Compounds - therapeutic use | Anti-Bacterial Agents - therapeutic use | Anti-Bacterial Agents - adverse effects | Roxithromycin - adverse effects | Roxithromycin - therapeutic use | Antibiotic Prophylaxis - methods | Clarithromycin - therapeutic use | Trimethoprim, Sulfamethoxazole Drug Combination - adverse effects | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Erythromycin - therapeutic use | Clavulanic Acid - adverse effects | Clavulanic Acid - therapeutic use | Azithromycin - adverse effects | Moxifloxacin - therapeutic use | Azithromycin - therapeutic use | Amoxicillin - therapeutic use | Amoxicillin - adverse effects | Quinolines - therapeutic use | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 50, pp. 109 - 117
... are approved for first-line or later-line use in the treatment of patients with mRCC [1–3] . Among these agents, 1 is a monoclonal antibody targeting vascular endothelial... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | PROGRESSION-FREE SURVIVAL | 1ST-LINE SUNITINIB | BLIND PHASE-III | OPEN-LABEL | INTERFERON-ALPHA | ONCOLOGY | 2ND-LINE TREATMENT | EXPRESSION LEVELS | CANCER-SPECIFIC SURVIVAL | CLINICAL-PRACTICE | DOSE TITRATION | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer
Journal Article
European Urology, ISSN 0302-2838, 2011, Volume 61, Issue 5, pp. 950 - 960
...) progression has led to the recognition of multiple molecular targets and advances in the therapeutic landscape... 
Urology | Molecular targets | Chemotherapy | Immunotherapy | Androgen pathway inhibitors | Biologic agents | Androgen receptor | Prostate cancer | Skeletal-related events | ADVANCED SOLID TUMORS | DOCETAXEL | PATHWAY ACTIVATION | MITOXANTRONE PLUS PREDNISONE | INHIBITION | RANDOMIZED PHASE-II | CLINICAL-TRIALS | UROLOGY & NEPHROLOGY | END-POINTS | HIGH-DOSE CALCITRIOL | Receptors, Vascular Endothelial Growth Factor | Anilides - therapeutic use | Phenylthiohydantoin - therapeutic use | Humans | Ipilimumab | Recombinant Fusion Proteins - therapeutic use | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Thiazoles - therapeutic use | Abiraterone Acetate | Quinolones | Antibodies, Monoclonal, Humanized | Taxoids - therapeutic use | Cancer Vaccines - therapeutic use | Clinical Trials, Phase III as Topic | Bone Neoplasms - drug therapy | Clusterin - therapeutic use | Prostatic Neoplasms - drug therapy | Carcinoma - secondary | Pyridines - therapeutic use | Carcinoma - drug therapy | Dasatinib | Prostatic Neoplasms - pathology | Prostatic Neoplasms - surgery | Carcinoma - surgery | Treatment Outcome | Vaccines, Synthetic - therapeutic use | Tissue Extracts - therapeutic use | Denosumab | Radium - therapeutic use | Phenylthiohydantoin - analogs & derivatives | Orchiectomy | Pyrimidines - therapeutic use | Androstadienes - therapeutic use | Quinolines - therapeutic use | Medical colleges | Hospitals | Development and progression | Metastasis | Tubulins | Cancer | Landscape | Conferences | Immunoregulation | Clinical trials | Data processing | Oncology | Src protein | Clusterin | Metastases | Angiogenesis | Signal transduction | Androgens | Antagonism | Databases | Reviews | Tubulin | Acetic acid
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 383, Issue 9918, pp. 723 - 735
Summary Although global morbidity and mortality have decreased substantially, malaria, a parasite infection of red blood cells, still kills roughly 2000 people... 
Internal Medicine | VIVAX MALARIA | MEDICINE, GENERAL & INTERNAL | MALAWIAN CHILDREN | CHILDHOOD CEREBRAL MALARIA | SUB-SAHARAN AFRICA | RANDOMIZED-TRIAL | ACUTE-RENAL-FAILURE | INFECTED ERYTHROCYTES | PLASMODIUM-FALCIPARUM MALARIA | VON-WILLEBRAND-FACTOR | PROSPECTIVE COHORT | Malaria, Falciparum | Malaria, Vivax | Pregnancy Complications, Infectious - parasitology | Humans | Asia, Southeastern - epidemiology | Pregnancy Complications, Infectious - physiopathology | Quinine - therapeutic use | Insecticide-Treated Bednets | Mefloquine - therapeutic use | Malaria - epidemiology | Sulfadoxine - therapeutic use | Pregnancy Complications, Infectious - prevention & control | Female | Seasons | Amodiaquine - therapeutic use | Drug Therapy, Combination | Drug Resistance | Insecticides - pharmacology | Pyrimethamine - therapeutic use | Drug Administration Schedule | Pregnancy Complications, Infectious - epidemiology | Chloroquine - therapeutic use | Malaria - diagnosis | Antimalarials - therapeutic use | Malaria - prevention & control | Pregnancy | Anopheles | Animals | Artemisinins - therapeutic use | Malaria Vaccines - administration & dosage | Malaria - pathology | Pregnancy Complications, Infectious - drug therapy | Primary Prevention - methods | Malaria - physiopathology | Malaria - complications | Quinolines - therapeutic use | Malaria - drug therapy | Africa South of the Sahara - epidemiology | Drug Combinations | Prognosis | Research | Malaria | Epidemiology | Distribution | Plasmodium falciparum | Medical research | Parasitic diseases | Mortality | Africa | Antimalarials | Medicine, Experimental | Insecticides | Mosquitoes | Microscopy | Ligands | Parasites | Blood
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 388, Issue 10043, pp. 518 - 529
...) pathway inhibitors into the therapeutic armoury. Although some tumours such as renal cell carcinoma, ovarian and cervical cancers, and pancreatic neuroendocrine... 
Internal Medicine | PHASE-III TRIAL | ADVANCED HEPATOCELLULAR-CARCINOMA | BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | PANCREATIC NEUROENDOCRINE TUMORS | TYROSINE KINASE INHIBITOR | RECURRENT OVARIAN-CANCER | ANTI-ANGIOGENIC THERAPY | RESISTANT PROSTATE-CANCER | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Humans | Drug Resistance, Neoplasm | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Angiogenesis Inhibitors - therapeutic use | Biomarkers, Tumor - metabolism | Female | Neovascularization, Pathologic - prevention & control | Molecular Targeted Therapy - methods | Receptor, TIE-2 - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Neoplasms - blood supply | Piperazines - therapeutic use | Angiopoietin-1 - antagonists & inhibitors | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Neoplasms - drug therapy | Biomarkers, Tumor - blood | Disease-Free Survival | Phthalazines - therapeutic use | Signal Transduction - drug effects | Neovascularization, Pathologic - drug therapy | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinolines - therapeutic use | Antimitotic agents | Pancreatic cancer | Melanoma | Neovascularization | Antineoplastic agents | Vascular endothelial growth factor | Prostate cancer | Cervical cancer | Drugs | Angiogenesis | Chemotherapy | Clinical trials | Oncology | Metastasis | Cancer therapies | Tumors | Cancer
Journal Article